Airway remodeling including increased airway smooth muscle (ASM) mass is a hallmark feature of asthma and COPD. We previously identified the expression of bitter taste receptors (TAS2Rs) on human ASM cells, and demonstrated that known TAS2R agonists could promote ASM relaxation and bronchodilation, and inhibit mitogen-induced ASM growth. In this study we explored cellular mechanisms mediating the anti-mitogenic effect of TAS2R agonists on human 
INTRODUCTION
Airway inflammatory diseases such as asthma and COPD are characterized by inflammation, mucus production, airway remodeling and hyperresponsiveness resulting in severe bronchoconstriction (4, 27, 45) . The chronic nature of these diseases leads to structural and functional changes in resident cells of the airway wall including ASM cells (27, 28, 39, 40) .
Histological evaluation of asthmatic lung samples reveals a significant increase in the ASM mass (8, 17, 19, 25) , which is correlated with asthma severity (2, 15, 55) . Alterations in ASM mass and phenotype are now appreciated as pathogenic mechanisms of obstructive lung diseases (6) .
G protein-coupled receptor (GPCR) signaling plays a vital role in the regulation of ASM contraction, relaxation, and proliferation (4, 10) and therefore, agonists/antagonists of GPCRs represent potentially efficacious anti-asthma medications. Current anti-asthma therapies, including beta-agonists and corticosteroids, aim at alleviating bronchoconstriction and inflammation, respectively, but have a very limited effect on remodeling (4) . Thus there is a pressing need for identifying new drugs that cause both ASM relaxation and inhibition of growth.
Recently we identified the expression of type II taste receptors (TAS2Rs) on human ASM cells and characterized intracellular signaling mediated via these receptors using a panel of known TAS2R agonists (12, 50) . Among the 25 known taste receptors at least three subtypes are highly expressed (T2R10, T2R14, T2R31) and three more are moderately expressed (T2R5, T2R4, T2R19) in human ASM. Expression of TAS2Rs on guinea pig and murine ASM has also been demonstrated recently (34, 47) . Extant TAS2R agonists include both synthetic and natural compounds. One group includes chloroquine and quinine, which activate T2R10, T2R14, and T2R31 expressed on human ASM cells (12, 35) . Stimulation of ASM cells with TAS2R agonists 4 resulted in an increase in intracellular calcium that was G , PLC-and IP 3 -dependent.
Interestingly, elevation of calcium upon TASR stimulation was associated with a robust relaxation of ASM cells and airway rings. This relaxation effect of TAS2R agonists was confirmed by three independent laboratories using mouse, guinea pig and human airways (12, 34, 47) . Studies using lung slices (human and murine) and in vivo aerosol challenge in murine models have demonstrated efficacious bronchodilation by TAS2R agonists. These observations posit TAS2R agonists as a new class of bronchodilators for clinical use. Recent study from our laboratory demonstrated that TAS2R agonists such as chloroquine and quinine inhibit mitogeninduced human ASM growth (50) . Furthermore, the anti-mitogenic effect of TAS2R agonist is mediated, at least partially, via inhibition of PI3 kinase pathway and arresting of cell cycle progression (50) .
Increases in ASM mass could result from multiple mechanisms including an increase in cell number (hyperplasia), size (hypertrophy), epithelial to mesenchymal transition (EMT), or decrease in cell death. Inhibition of ASM growth by anti-mitogenic agents can occur via targeting of any of these mechanisms including autophagy and mitochondrial-initiated cell death.
In this study we aimed to determine additional cellular mechanisms involved in the antimitogenic effect of TAS2R agonists, chloroquine and quinine on human ASM cells. Using advanced microscopic imaging and biochemical tools herein we demonstrate that TAS2R
agonists modulate mitochondria dynamics and function leading to ASM cell death. Chloroquineand quinine-induced ASM cell death was reversed by pre-treating cells with befilomycin A1, an autophagy inhibitor, suggesting the role of autophagy. Interestingly, the anti-mitogenic effect of TAS2R agonists on human ASM cells was attenuated by inhibiting Bnip3, a mitochondrial protein, using dominant negative Bnip3 or a DLP1 inhibitor Mdivi-1, suggesting a central role 5 for mitochondrial protein Bnip3 and autophagy in TAS2R agonist-mediated anti-mitogenic effect on human ASM.
METHODS

Materials
Antibodies against Mfn1, Mfn2, and Bnip3 were from Abcam (Burlinggame, CA, USA).
DLP1 and Opa1 antibodies were from BD Bioscience (Franklin Lakes, NJ, USA). VDAC, Beclin-1 and ATG-5 antibody were purchased from Cell Signaling Technology (Beverly, MA, USA). IRDye 680 or 800 secondary antibodies were from Rockland (Gilbertsville, PA, USA).
Quantitative PCR arrays and SYBR green reagents were purchased from Qiagen (Valencia, CA, USA). MTT cell proliferation assay kit, MitoTracker Green and MitoSox red are from Thermo
Fisher Scientific (Pittsburg, PA, USA). siRNA oligos were obtained from Dharmacon (Lafayette, CO, USA). Rabbit-anti LC3-β, anti--actin, Bafilomycin A1 (Baf A1), 3-Methyl adenine (3-MA), chloroquine, quinine, saccharine, and other reagents were obtained from Sigma (St. Louis, MO, USA) or from previously identified sources (12, 50) . Wild type and dominant-negative Bnip3 adeno-associated virus were from ViGene Bioscience (Rockville, MD, USA)
Cell culture
Human ASM cultures were established from human tracheae or primary bronchi using enzyme dissociation method, and were grown in F-12 medium with supplements as described previously (11, 12, 37) . ASM cells in subculture during the second through fifth cell passages were used. The cells were maintained in F-12 medium with no serum and supplemented with 1% insulin transferrin selenium (arresting medium) for 24-48 h before the experiments.
Isolation of mitochondria 6
Mitochondria were isolated from ASM cells after the treatments with TAS2R agonists using Mitochondria Isolation Kit (Miltenyi Biotec) (21, 36). Briefly, 1x10 7 ASM cells were collected, washed with PBS and resuspended in 1 ml lysis buffer. Cell homogenates were prepared using a dounce homogenizer and incubated with 50 l of anti-Tom22 coated beads for 1 h with gentle shaking at 4°C. After the non-specific binding was washed out in the magnetic field, mitochondria were isolated for analysis.
siRNA transfection and viral (Adeno-Associated Virus, AAV) infection
siRNA transfection was performed in human ASM cells as described previously (49) .
Briefly, cells were seeded in 6-well plates one day before transfection. 
Propidium iodide (PI) staining
Human ASM cells were incubated with 4 l of PI (10 mg/ml) in 1 ml of medium in a CO 2 incubator. The staining solution was removed after 5 min followed by three washes with PBS. ASM cell images were acquired using a confocal (λ ex 535 nm, λ em 617 nm) microscope.
MTT and CyQuant assay
MTT and CyQuant assays were performed as described previously (50) . Human ASM cells were grown to sub-confluence in 96-well cell culture plates before switching to growth arrest media for 24 h (F12 + 1% ITS) and then treated with TAS2R agonists in the presence or absence of PDGF (10 ng/ml) for 24 h. In some cases cells were pretreated with 3 M Mdivi-1 for 2 h before treating with TAS2R agonists ± PDGF. At the end of the treatment, media was removed and cells incubated with MTT or CyQuant reagent for 4 h or 1 h respectively, and absorbance or fluorescence determined using a plate reader.
Immunostaining and light microscope imaging
Cells were plated onto pre-cleared glass coverslips in 6-well culture dishes and fixed for 15 min at 4°C in 3% paraformaldehyde (PFA) and then permeabilized by incubation for 5 min at 4°C using 3% PFA and 0.3% Triton X-100. 
Electron microscopy (EM) studies
The ultrastructural details of the cell were assessed using transmission electron microscopy (TEM) to measure autophagosome formation and assess mitochondrial integrity (46) . Cells were grown in 6-well culture plates, treated as described above and processed further for Transmission Electron Microscopy. Imaging was performed at the core facility at University of Maryland, Baltimore using FEI Tecnai T12 high-resolution microscope.
Western blotting
Western blotting (immunoblotting) was performed as described previously (42, 43). The images were acquired by Odessey image scanner (LiCor). Equal loading of protein was ensured by determining the expression of -actin or tubulin.
RNA isolation, RT-PCR and Real-Time PCR array
Cells grown on 6-well plates were treated with PDGF or vehicle with or without pretreatment with TAS2R agonists for 24 h, and total RNA was harvested as described in our previous studies (37, 50). Total RNA (1 g) was converted to cDNA by RT reaction and the reaction stopped by heating the samples at 94 o C for 5 min. Quantitative real-time PCR was performed using RT 2 Profiler PCR Array for mitochondria genes (PAHS-087Z) using Applied
Biosystems real time PCR machine (Mx3005). Raw Ct values were obtained using software recommended threshold fluorescence intensity. Gene expression data was calculated as described previously using expression of internal control gene (GAPDH) (12, 49) .
Assessment of Mitochondrial Membrane Potential and Reactive Oxygen Species (ROS) generation 9
Mitochondrial membrane potential and ROS measurements were performed as described previously (43). Briefly, after the treatment with TAS2R agonists, ASM cells were incubated with mitochondrial membrane potential dye Tetramethylrhodamine, ethyl ester (TMRE) or mitochondrial ROS probe MitoSox red for 30 min, then washed with PBS to remove the unincorporated dyes. Mitochondrial membrane potential and ROS generation were monitored by live-cell imaging using a confocal microscope. Mitochondria images were acquired by Fluoview (Olympus) using a 60x Oil objective and analyzed using NIH ImageJ 1.44 software.
Statistical analyses
Data are presented as mean ± SEM values from at least three experiments, in which each experiment was performed using a different ASM culture derived from a unique donor.
Individual data points from a single experiment were calculated as the mean value from three replicate observations, and reported as fold change from vehicle treated group. Statistically significant differences among groups were assessed by either student t-test or ANOVA using Prism Graphpad software (Graphpad, La Jolla, CA, USA), with values of p<0.05 sufficient to reject the null hypothesis.
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RESULTS
TAS2R agonists induce ASM cell death
We used PDGF to induce ASM growth and determined the effect of three different TAS2R agonists chloroquine (Chloro), quinine (Quin) and saccharin (Sacc) on mitogen-induced ASM growth. ASM cell survival was significantly decreased by chloroquine and quinine ( Figure   1A ) supporting the anti-mitogenic effect of TAS2R agonists on human ASM cells (50) . 
TAS2R agonists impair mitochondrial function in human ASM cells
Our TEM studies demonstrated that chronic treatment of human ASM cells with TAS2R
agonists increased accumulation of deformed mitochondria ( Figure 1E ). Therefore, we next assessed whether mitochondrial function was altered by TAS2R agonists. Indeed, the vehicle-treated controls; n=24, p<0.05) ( Figure 2C ). Collectively, these data strongly suggest that chronic exposure of human ASM cells to TAS2R agonists, chloroquine or quinine results in mitochondrial dysfunction as indicated by a significant decrease in mitochondrial membrane potential, cellular ATP levels, and a significant increase in mitochondrial ROS.
TAS2R agonists increase mitochondrial fragmentation in human ASM cells
To further understand the subcellular effect of TAS2R agonists in human ASM cells, we determined the effect of chloroquine and quinine on mitochondrial dynamics. In control cells exposed to vehicle, mitochondria were interconnected and formed tubular and granular network.
Exposure of cells to TAS2R agonists caused an increase in fragmented mitochondria as determined by live-cell confocal imaging ( Figure 3A) . The mitochondrial morphology data were further analyzed quantitatively using form factor (an indicator of mitochondria branching) and aspect ratio (an indicator of mitochondria length). Chloroquine and quinine significantly increased mitochondrial fragmentation ( Figure 3A-C Figure 3C ). Interestingly, exposure of human ASM cells to TAS2R
agonists did not significantly change expression levels of mitochondrial dynamics proteins including dynamin-like protein 1 (DLP1), optic atrophy 1 (Opa1), mitofusin 1 (Mfn1) and mitofusin 2 (Mfn2) indicating the alteration in mitochondrial dynamics is not due to the changes in the expression levels of the mitochondrial dynamic proteins ( Figure 3D ). These data suggest that chronic exposure of human ASM cells to chloroquine and quinine alters mitochondrial dynamics leading to mitochondrial fragmentation.
TAS2R agonists increase Bnip3 expression and DLP1 mitochondrial localization in human ASM cells
To determine the molecular mechanisms by which chloroquine and quinine change mitochondrial dynamics and function, we performed RT 2 profiler PCR Array analysis (Figure 4 ).
Real-time PCR analysis revealed significant upregulation of Bnip3 expression in human ASM cells exposed to chloroquine and quinine (1.59 0.05 and 2.41 0.07 fold control, chloro or quin+PDGF respectively; p<0.05, n=4) ( Figure 4A-B) .
To explore the molecular mechanisms by which chloroquine and quinine alter mitochondria morphology and function, we isolated mitochondria from human ASM cells agonists up-regulate Bnip3 expression, which increases DLP1 levels in mitochondria resulting in mitochondrial fragmentation and dysfunction.
Bnip3 siRNA partly reverses TAS2R agonists-induced mitochondrial fragmentation
To confirm the role of Bnip3 in TAS2R-induced mitochondrial fragmentation, we down- Down-regulation of Bnip3 expression by siRNA did not have significant effects on the protein levels of DLP1 (data not shown). These data strongly suggest that Bnip3 plays a role in TAS2R
agonists-induced mitochondrial fragmentation. However, current siRNA/shRNA approaches (that work in primary ASM) are not amenable to analyses of ASM growth and we were not able to demonstrate the role of Bnip3 in the regulation of ASM growth by TAS2R agonists.
Therefore, we used additional approaches to down-regulate mitochondrial Bnip3 levels.
Dominant-negative Bnip3 inhibits TAS2R agonists-induced cell death in human ASM cells
We have demonstrated that TAS2R agonists-induced increase in mitochondrial fragmentation and cell death in human ASM cells is associated with increased Bnip3 expression.
To further understand the role of Bnip3 in TAS2R agonists-induced mitochondrial fragmentation and cell death in ASM cells, we generated adeno-associated virus (AAV) expressing wild type (WT) or dominant-negative (DN) Bnip3 lacking the c-terminal mitochondrial localization domain. The truncated Bnip3 does not localize to mitochondria, and functions as the dominantnegative form of Bnip3. The infection efficiency was determined by GFP-fluorescence ( Figure   6A ). The expression of WT and DN Bnip3 was confirmed by western blotting ( Figure 6B ).
Using this approach, we determined the role of Bnip3 in TAS2R agonists-induced cell death in Bnip3 expressing human ASM cells ( Figure 6C ). TAS2R agonists-induced cell death was significantly decreased in human ASM cells transfected with DN-Bnip3 compared to cells transfected with WT-Bnip3 (a 66% decrease in chloro+PDGF group and a 73% decrease in quin+PDGF group, n=4; p<0.01 for both). These findings demonstrate that TAS2R agonistsinduced ASM cell death is mediated via Bnip3 localization to mitochondria and mitochondrial mechanisms. Autophagy causes proteolytic degradation of cytosolic components. There are three types of autophagy: macro-autophagy, micro-autophagy, and chaperone-mediated autophagy. All these three processes degrade cytosolic components at the lysosomes (38). This is mediated by a special organelle called autophgosome. Autophagic process consists of several sequential steps including sequestration, degradation and amino acid generation. Autophagy is active in most of the cells in the body at basal level to remove damaged organelles and proteins. However, autophagy can also be stimulated in stress situation such as nutrient depletion. During nutrient 16 shortage, autophagy provides the constituents required for survival. Autophagy is an evolutionary conserved process to maintain the energy balance (30, 32, 44) . Recent studies have demonstrated that autophagy plays a role in a variety of physiological and pathological processes besides adaptation to starvation such as development, aging, cancer and muscle disorder (38).
Autophagic removal of damaged proteins, organelles including mitochondria, endoplasmic reticulum, peroxisomes serves as an important quality control mechanism for cell survival (16) .
The regulation of autophagy in mammals is very complicated and involves multiple signaling pathways (5) (41) (7). Dysregulation of autophagy is linked to cell death (9, 33) . For example, accumulation of ATGs has been found in mammalian cells undergoing autophagic cell death, which requires the presence of Bcl-2 family proteins (51). Furthermore, excessive autophagy in cells has been shown to induce cell death (9, 33) . Our findings in this study demonstrate that chloroquine and quinine mediated cell death in human ASM cells involves autophagy.
Mitochondria are highly dynamic organelles that undergo fission and fusion constantly.
Mitochondrial fission and fusion are the key determinants of mitochondria morphology and function (20) . Through fission and fusion mechanisms, mitochondria change their length and number. In addition, fission and fusion allow mitochondria to exchange lipid membranes and intra-mitochondrial substance. Such an exchange is essential for maintaining healthy mitochondria population. The shape of the mitochondria is important for the distribution of mitochondria especially in highly polarized cells such as neurons. Excessive mitochondria fission facilitates cell death and the release of inter membrane space substances (31, 56, 57) .
Mitochondria become elongated when fusion is dominant or fission is insufficient. In contrast, Human ASM cells were serum starved for 24 h and then treated with either vehicle or 125 M TAS2R agonists (chloro and quin) in the absence and presence of 10 ng/ml PDGF (P) for 24 h.
A. Mitochondrial membrane potential was measured using TMRE (*p<0.05, n=9). B. Cellular ATP levels were measured as luciferase intensity (*p<0.05, n=3). C. Mitochondrial ROS was measured by confocal live-cell imaging using mitoSox red (*p<0.05, n=24). 
